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Abstract
The effects of thrombin on adenylyl cyclase activity were examined in rat adrenal medullary microvascular endothelial
 .cells RAMEC . Confluent RAMEC monolayers were stimulated for 5 min with cAMP-generating agents in the absence
and presence of thrombin, and intracellular cAMP was measured with a radioligand binding assay. Thrombin 0.001–0.25
.Urml dose-dependently inhibited IBMX-, isoproterenol- and forskolin-stimulated cAMP accumulation. A peptide agonist
of the thrombin receptor, g-thrombin, and the serine proteases trypsin and plasmin, also inhibited agonist-stimulated cAMP
levels, while proteolytically inactive PPACK- or DIP-a-thrombins were without effect. Moreover, the thrombin inhibitor
hirudin abolished the inhibitory effect of thrombin but not of the peptide agonist. These results suggest that the inhibitory
action of thrombin on cAMP accumulation is mediated by a proteolytically-activated thrombin receptor. The inhibitor of
G -proteins pertussis toxin abolished the inhibitory effect of thrombin on isoproterenol- or IBMX-stimulated cAMPi
production, while the phorbol ester PMA partly impaired it. The protein kinase C inhibitors staurosporine or H7 and the
intracellular Ca2q chelator BAPTA-AM were without effect. Collectively, our data suggest that the thrombin receptor in
RAMEC is negatively coupled to adenylyl cyclase through a pertussis toxin-sensitive G -protein.i
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1. Introduction
Thrombin is a plasma serine protease that induces
blood coagulation and also stimulates immediate and
long-term responses on various cell types that vary
w xdepending on the cell type 1,2 . In endothelial cells
 .EC thrombin increases monolayer permeability,
modulates proliferation, induces migration, and in-
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creases the expression of prostacyclin, interleukin-1,
nitric oxide, endothelin, tissue factor, and platelet
w xactivating factor 3–8 . Most of the cellular actions of
thrombin are mediated through activation of a cell
surface receptor belonging to the 7-transmembrane
spanning domain, G-protein coupled receptor family
w x9 . The mechanism of activation of this receptor
involves proteolytic cleavage by thrombin after an
arginine site of its NH -terminus. The newly exposed2
NH -terminus of the receptor then binds intramolecu-2
larly to the body of the receptor and triggers cellular
w xsignaling 9 . Synthetic peptides, mimicking the amino
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acid sequence of the new NH -terminus, are able to2
reproduce many of the vascular actions of thrombin
w x10 . The effects of thrombin are usually short-lived,
as the thrombin receptor is rapidly desensitized either
due to proteolysis, phosphorylation, or internalization
w x11 .
The hormone-stimulated adenylyl cyclase pathway
w xis a well described signaling system 12 . The enzyme
adenylyl cyclase is coupled to cell surface receptors
 .  .through both stimulatory G and inhibitory Gs i
GTP-binding proteins, it catalyzes the formation of
 .the second messenger cyclic AMP cAMP , and it is
expressed in at least 8 distinct isoforms with different
w xregulatory properties and tissue distributions 13–17 .
Cyclic AMP participates in the regulation of diverse
fundamental cellular processes such as proliferation
and differentiation, as well as cell type-specific func-
tions. Recently, it has become apparent that, in addi-
tion to its second messenger function, cAMP acts as a
gate which regulates signal flow through other path-
w xways 18 . The discovery of adenylyl cyclase isoform
multiplicity and diversity, together with important
new functions ascribed to cAMP, have renewed inter-
w xest in this classical signaling pathway 17,18 .
The interaction of thrombin with the adenylyl cy-
clase signaling system has been studied in several
cell types. For example, in platelets it was shown that
 .low -0.1 Urml concentrations of thrombin inhibit
cyclic AMP accumulation through activation of a
 . w xpertussis toxin PTX -sensitive G protein 19,20 .i
This observation was later confirmed in fibroblasts
w x  .21 , and in human erythroleukemia HEL
w xmegakaryoblastic cell membranes 22 . However, in
intact HEL cells, the same study found that similar
doses of thrombin markedly potentiated the cAMP
response to prostaglandin and cAMP-increasing
w xagents 22 . A stimulatory effect of thrombin on
cAMP levels was recently also reported in human
w xerythroid progenitor cells 23 . In human umbilical
 .vein endothelial cells HUVEC , one study found a
small but significant increase in cAMP levels follow-
w xing stimulation with 1 Urml thrombin 24 . Another
found a small effect of thrombin on cAMP levels that
w xwas significantly augmented by cholera toxin 25 ,
while yet other studies reported that thrombin induces
a several-fold increase in cAMP levels in the pres-
w xence of the phosphodiesterase inhibitor IBMX 3,26 .
Based on such evidence, a recent review concluded
w xthat thrombin increases cAMP levels in EC 11 . In
another study, however, no effect of thrombin on
intracellular cAMP levels was detected in bovine
w xpulmonary artery EC 27 . To date, no inhibitory
effects of thrombin on cAMP production have been
reported in EC.
In addition to the rather ill-defined role of throm-
bin in regulating cAMP, EC activation by thrombin
involves a number of other well-characterized signal-
ing cascades. Most notably, binding of thrombin to
its receptor activates phospholipase C , which in turnb
catalyzes the transient production of inositol trisphos-
phate and diacylglycerol from membrane phos-
w xphatidylinositols 10 . Inositol trisphosphate mobi-
lizes the release of Ca2q from internal stores and also
contributes to the entry of extracellular Ca2q, whereas
 .diacylglycerol activates protein kinase C PKC .
Thrombin can also activate phospholipase D, which
catalyzes the sustained formation of diacylglycerol
from phosphatidylcholine and, thus, the subsequent
w xsustained activation of PKC 10 . Interestingly, both
PKC and intracellular Ca2q can affect adenylyl cy-
w xclase activity through cross-talk interactions 17,28 .
We previously reported the isolation and character-
ization of a microvascular EC type from the rat
w xadrenal medulla, RAMEC 29 . These cells express a
w xdistinct set of adenylyl cyclase isoforms 30 . Here,
we report that thrombin inhibits basal and agonist-
stimulated cAMP accumulation in RAMEC; this in-
hibitory action requires proteolytic activation of the
thrombin receptor and is sensitive to PTX. These
findings suggest that the thrombin receptor in this
cell type is negatively coupled to adenylyl cyclase
through a G -protein. Further, we present evidencei
suggesting that the inhibitory effect of thrombin on
cAMP in RAMEC is independent of second messen-
gers generated downstream of the phospholipase C
cascade.
2. Materials and methods
2.1. Materials
Human a- and g-thrombins were prepared as pre-
w xviously described 31 . These preparations had fib-
rinogen clotting activities of 2712 and 10.24 Urmg
protein, and active site titrations of 2.98=10y5 and
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4.57=10y5 M, respectively. 1 U of a-thrombin
corresponds to a concentration of approx. 10 nM.
 .D-Phe-Pro-Arg-chloromethyl ketone PPACK -a-
 .thrombin, and diisopropylphosphoryl DIP -a-
w xthrombin were prepared as previously described 32 ,
and were essentially enzymatically inactive. The syn-
thetic thrombin receptor agonist peptide SFLL-
 .RNPNDKYEPF TRAP was obtained from Penin-
 .sula Laboratories Belmont, CA . Bovine trypsin type
1, bovine plasmin and porcine pancreatic elastase
were purchased from Sigma Chemical Co. St. Louis,
.MO , and their proteolytic activity is defined in units
as described in the Sigma catalog. Forskolin, iso-
 . proterenol, dibutyryl cyclic AMP dbcAMP , 1- 5-
.  .isoquinolinylsulfonyl -2-methylpiperazine H7 , 4-
 .phorbol-12-myristate-13-acetate PMA , collagenase
type I, staurosporine, and EDTA were also obtained
from Sigma. Cell permeant 1,2-bis 2-aminophe-
. X Xnoxy ethane-N,N,N ,N -tetraacetic acid-acetomethyl-
 .ester BAPTA-AM , and fura-2 acetoxymethylester
 .fura-2rAM were obtained from Molecular Probes
 .  .Eugene, OR . Pertussis toxin PTX was obtained
 .from List Laboratories Cambell, CA . Dulbecco’s
 .modified Eagle’s medium DMEM , L-glutamine, and
cell culture grade trypsin-EDTA were purchased from
 .Gibco Grand Island, NY . Fetal calf serum was
 .obtained from HyClone Labs Logan, UT . Penicillin
and streptomycin were supplied by Fisher Pitts-
.burgh, PA . Fungizone was obtained from the local
pharmacy. Disposable, cell culture grade labware was
 .supplied by Corning Corning, NY .
2.2. Endothelial cell culture
Microvascular endothelial cells from the rat adrenal
 .medulla RAMEC were isolated with a modification
w xof the method of Mizrachi et al. 33 . Briefly, after
removal of the adrenal glands from 5–6 animals, the
medullae were excised under a stereo microscope,
triturated, and digested with collagenase type I. Pure
cultures of endothelial cells were obtained following
differential plating and, after establishing colonies of
primary isolates, cloning by limited dilution. RAMEC
were grown in DMEM medium supplemented with
 .10% vrv fetal calf serum, 2 mM L-glutamine, 100
Urml penicillin, 100 mgrml streptomycin, and 5
mgrml fungizone, and passaged with trypsin every 4
days. The endothelial nature of all cultures was rou-
tinely confirmed by their hystiotypic, contact-in-
hibited cobblestone morphology, and by the ability of
the cells to endocytose di-indocarbocyamine labelled,
acetylated low-density lipoprotein and to express von
w xWillebrand factor as previously described 29 .
RAMEC from passages 5 to 20, which were used in
our experiments, maintain expression of all EC-
specific characteristics mentioned above.
2.3. Measurement of cAMP
Cells were plated in 12-well plates at a density of
15 000 cells per cm2. One day after reaching conflu-
 .ence 3–4 days after plating , the cells were washed
with serum-free medium twice and then stimulated
with the various compounds for 5 min in serum-free
medium. Physiological activation of the adenylyl cy-
clase cascade was obtained with the b-adrenergic
receptor agonist isoproterenol. In preliminary experi-
ments, we established that maximal stimulation of
cAMP accumulation was obtained with 1 mM iso-
 .proterenol data not shown . Therefore, this concen-
tration of the agonist was used in all subsequent
experiments. The diterpene, forskolin, which binds
to, and activates adenylyl cyclase with an EC rang-50
w xing between 5–40 mM 34,35 , was also used, at
concentrations of 10 or 100 mM. Further, a lipid-
soluble analogue of cAMP, dbcAMP, which is taken
up by cells, was used to obtain high intracellular
cAMP levels without activation of the upstream sig-
naling cascade. Finally, the phosphodiesterase in-
hibitor IBMX was used to inhibit cAMP degradation
by phosphodiesterases. This is often necessary as the
intracellular concentration of cAMP in many cell
types, including EC, despite constant production by
basally active adenylyl cyclase, is usually kept very
low due to continuous degradation of cAMP by
w xphosphodiesterases 35 .
At the end of an experiment, cAMP was extracted,
and measured by a competitive radioligand binding
w xassay, as previously described 35 . The sensitivity of
the cAMP assay was 0.25 pmol cAMP per assay
tube. The protein content of the wells was determined
with a commercially available colorimetric assay kit
 .Pierce, Rockford, IL according to the manufacturer’s
instructions.
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2.4. Measurement of intracellular Ca2q concentra-
tion
Intracellular Ca2q concentration was measured as
w xdescribed elsewhere 36 . Briefly, cells were seeded
on glass cover slips at 10 000 cells per cm2 and used
2–3 days after plating. The cells were incubated for
30 min at 378C with 2mM fura-2rAM dissolved in
modified Krebs’ buffer of the following composition
 .in mM : 140.0 NaCl, 1.5 CaCl , 5.9 KCl, 1.2 MgCl ,2 2
11.5 HEPES-NaOH, and 10.0 glucose, pH 7.4. The
cells were placed on the stage of a Zeiss inverted
 .microscope equipped with a 40= fluorite objective
and superfused with Krebs buffer at a rate of 1.5
mlrmin. Individual cells were excited alternatively at
360r390 nm via a rotating filter wheel speed of 2–3
y1.s , and fluorescence was measured at 510 nm.
Autofluorescence was measured on cell-free parts of
the coverslips and automatically subtracted from the
Ca2q signals. Apparent free Ca2q concentrations were
calculated from the ratio of the background-corrected
fluorescence signals. The effective dissociation con-
stant of Fura-2 was obtained from in vitro calibra-
w xtions 36 .
2.5. Statistical analysis
Each experiment included triplicate wells for each
condition tested and was repeated at least 3 times,
unless otherwise specified. The results for each ex-
perimental group are expressed as mean"S.E.M.
The significance of variability amongst various groups
was determined by one-way analysis of variance
 .ANOVA test . Calculations of IC were done with50
the Origin software package MicroCal Software,
.Northampton, MA .
3. Results
3.1. Thrombin modulation of basal and agonist-
stimulated cAMP accumulation
Incubation of RAMEC for 5 min with isoprote-
renol, forskolin, IBMX, or dbcAMP, resulted in sig-
nificantly elevated cAMP levels as compared to un-
 .stimulated cells Table 1 . When applied to the cells
for 1–30 min, and at concentrations of up to 1 Urml,
a-thrombin did not significantly affect intracellular
 .cAMP levels Table 1 and data not shown . When
applied immediately before addition of the cAMP-
elevating compounds, 0.1 Urml of a-thrombin sig-
nificantly inhibited cAMP accumulation induced by
isoproterenol, forskolin, or IBMX, but it did not
reduce high intracellular cAMP levels obtained with
 .dbcAMP Table 1 . Thus, the inhibitory effect of
thrombin does not result from its direct effect on the
formed cAMP, but occurs at a step of the adenylyl
cyclase cascade prior to cAMP formation.
The inhibitory effect of thrombin on both basal in
.the presence of IBMX as well as isoproterenol- and
forskolin-induced cAMP levels was further studied.
Significant inhibition of the effect of 1 mM of iso-
proterenol was found with 0.001 Urml of a-throm-
bin; this inhibition showed an IC of approx. 0.001550
Urml, and reached a maximum level of 85% inhibi-
Table 1
Effect of various cAMP-generating compounds on intracellular cAMP levels in RAMEC in the absence and presence of a-thrombin
a .  .  .Stimulus No thrombin pmol cAMPrmg protein qThrombin pmol cAMPrmg protein Inhibition %
 .None ns17 18.6"2 17.7"2.4 4.8"1.6
))) .Isoproterenol 1 mM ns17 919 "238 161 "61 84.9"2.2
)) .Forskolin 10 mM ns6 245 "82 114 "11 57.5""10.3
)) .Forskolin 100 mM ns16 7474 "907 3202 "369 57.3"4.2
)) .IBMX 1 mM ns9 184 "35 105 "24 47.6"4.0
 .DbcAMP 50 mM ns4 95 "115 92 "54 1.4"3.5
 .DbcAMP 500 mM ns4 1027 "209 1008 "608 2.5"8.6
Thrombin was used at 0.1 Urml. Values are mean"S.E.M. of the number of experiments indicated.
a Values in this column denote percent inhibition of agonist-stimulated cAMP accumulation in the presence of thrombin, extracted from
the raw data presented in the other 2 columns. Basal cAMP levels have been deducted in each case before calculation of the inhibitory
effect of thrombin. Two or three asterisks indicate P-0.01 and P-0.001 level of statistical significance, respectively.
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 .tion at 0.1 Urml of a-thrombin Fig. 1 . In the cases
of forskolin- or IBMX-induced cAMP levels, the
threshold concentrations of thrombin required to elicit
detectable inhibition were right-shifted by approx.
one order of magnitude, while its maximal inhibitory
effect on both agents was approx. 50–60% and was
 .reached also with 0.1 Urml Table 1, Fig. 1 . The
inhibitory effect of higher thrombin concentrations
 .up to 1 Urml was unchanged in the case of iso-
proterenol, but it was slightly reduced in the cases of
 .IBMX and forskolin Fig. 1 and data not shown .
The time requirements for thrombin inhibition were
determined by exposing the cells to a-thrombin for
0–15 min, while isoproterenol was added only during
the last 5 min of the incubation period. The inhibitory
effect was maximal when a-thrombin was applied
concomitantly with, or up to 2 min before, addition
of the agonist, and gradually declined if thrombin
 .was applied for longer or shorter periods Fig. 2 .
This rapid fall of thrombin’s effect is consistent with
the previously reported desensitization of the throm-
w xbin receptor shortly after activation 11 .
To ensure that the reduction of intracellular cAMP
levels in thrombin-treated cells was not due to in-
creased extrusion of cAMP from the cell, we mea-
sured both the intracellular and medium content of
cAMP in cells stimulated with either isoproterenol or
Fig. 1. Effect of thrombin on isoproterenol-, forskolin-, and
IBMX-stimulated cAMP accumulation in RAMEC. The cells
were stimulated for 5 min with either 1 mM isoproterenol ISO,
.  .squares , 100 mM forskolin FOR, triangles , or 1 mM IBMX
 .circles in the presence of increasing amounts of a-thrombin
 .0.00025–0.25 Urml . Results are expressed as percent inhibi-
tion of the agonist-stimulated cAMP levels in the presence of
thrombin and represent the mean"S.E.M. from 3 independent
experiments, each performed in triplicate wells.
Fig. 2. Time-dependence of the effect of thrombin on isoprote-
renol-induced cAMP accumulation. The cells were stimulated for
 .5 min with 1 mM isoproterenol. Thrombin 0.025 Urml was
added to the cells, 10, 5, or 2 min before, simultaneously with, or
2 min after, isoproterenol These time points correspond with
 .graph points y10, y5, y2, 0, and 2 min, respectively . Results
are expressed as pmol cAMPrmg protein and represent the
mean"S.E.M. of triplicate determinations from one representa-
tive experiment out of two that gave similar results.
forskolin in the presence and absence of thrombin.
These experiments showed that the thrombin-induced
decrease in agonist-stimulated intracellular cAMP ac-
cumulation is not due to increased extrusion of cAMP
 .in the media data not shown .
3.2. Thrombin receptor in˝ol˝ement
Thrombin activates a G protein-coupled cell sur-
face receptor by proteolytic cleavage and exposure of
a new NH -terminus, which in turn binds to and2
w xactivates the receptor 9 . A synthetic thrombin recep-
 .tor activating peptide TRAP with sequence mimick-
ing this terminus activates the receptor in the absence
of thrombin and is able to reproduce many of the
w xcellular actions of this protease 9,10 . A concentra-
tion of 10 mM of TRAP inhibited isoproterenol-
induced cAMP accumulation to a similar extent as
 .0.025 Urml of a-thrombin Table 2 . The reduced
efficiency of the peptide by more than 3 orders of
.magnitude in comparison to thrombin is probably
due to the ability of one thrombin molecule to cleave
and thus activate many receptor molecules, while
each molecule of TRAP can only bind to and activate
w xonly one receptor molecule 9 . Further, g-thrombin,
which lacks the fibrinogen binding site of native
w xa-thrombin but retains full proteolytic activity 31 ,
inhibited isoproterenol-stimulated cAMP accumula-
 .tion almost as efficiently as a-thrombin Table 2 .
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Table 2
Inhibitory effect of TRAP, active and inactive thrombin analogs,
and other proteases on isoproterenol-stimulated cAMP levels in
RAMEC
 .Stimulus % Inhibition n
Set A:
)) .  .a-thrombin 0.025 Urml 72.0"3.6 4
)) .  .TRAP 10 mM 54.8"5.4 4
)) .  .g-thrombin 0.025 Urml 65.2"7.0 4
 .  .PPACK-a-thrombin 25 nM 2.4"4.3 n.s. 3
 .  .DIP-a-thrombin 25 nM 7.8"6.7 n.s. 2
Set B:
)) .  .a-thrombin 0.025 Urml 77.8"6.3 3
) .  .trypsin 0.1 Urml 32.3"5.4 3
) .  .trypsin 1 Urml 53.9"7.5 3
) .  .plasmin 0.2 Urml 35.0"6.8 3
 .  .elastase 0.2 Urml 14.3"9.3 n.s. 2
Values are mean"S.E.M. of the number of experiments indi-
cated in the parenthesis. 0.025 Urml of a-thrombin correspond
to a concentration of approx. 0.25 nM. Results are expressed as
percent inhibition of agonist-stimulated cAMP accumulation in
the presence of the indicated compounds. In each case, basal
cAMP levels were deducted from values in the stimulated cells
before calculation of the inhibitory effect of each compound.
One or two asterisks indicate P -0.05 and P -0.01 level of
statistical significance, respectively.
n.s. not significant.
By contrast, the proteolytically inactive thrombin
w xanalogs PPACK-a-thrombin and DIP-a-thrombin 32
had no effect on agonist-induced cAMP accumula-
tion, even when used at concentrations 100 times
 .higher than a-thrombin Table 2 . Finally, the in-
hibitor of thrombin activity, hirudin, reduced the
inhibitory action of thrombin, but had no effect on
 .the inhibitory action of TRAP Fig. 3 . These data
suggest that the inhibitory action of thrombin on
agonist-induced cAMP accumulation is mediated by
a proteolytically-activated thrombin receptor.
3.3. Inhibition by other proteases
It has been shown that activation of the thrombin
receptor following proteolytic cleavage is not a unique
property of thrombin but can also be achieved with
other serine proteases possessing similar cleavage site
w xspecificity, such as trypsin and plasmin 9,37 . Both
trypsin, a lysinerarginine-specific protease, and plas-
min, which has a similar cleavage site specificity as
trypsin but with higher specificity for lysine, signifi-
cantly inhibited isoproterenol-stimulated cAMP accu-
mulation. However, their effect was smaller than that
of thrombin even when used at several fold higher
 .proteolytic activities than thrombin Table 2 . By
contrast, elastase, which hydrolyses amides and es-
 .ters, was without effect Table 2 . These data provide
further evidence that proteolytic activation of the
thrombin receptor by other serine proteases is suffi-
cient for inhibition of agonist-induced cAMP accu-
mulation, although alternative explanations are possi-
 .ble see Discussion .
3.4. Pertussis toxin sensiti˝ity
Adenylyl cyclase is under the dual control of
w xstimulatory and inhibitory G-proteins 12 . Inhibitory
G -proteins that couple extracellular receptors toi
adenylyl cyclase can be inactivated by pertussis toxin
 . w xPTX -catalyzed ADP ribosylation 19 . To test
whether such proteins are involved in thrombin’s
inhibitory effect, we preincubated RAMEC monolay-
ers with various concentrations of PTX 0.1–500
.ngrml for 4 h before agonist application. A concen-
tration of 10 ngrml of PTX effectively abrogated the
inhibitory effect of thrombin on isoproterenol-
 .stimulated cAMP accumulation Fig. 4a . It should be
noted that PTX, even at a higher concentration 100
. ngrml , did not affect either basal 17.2"1.7 and
Fig. 3. Effect of hirudin on the inhibitory action of thrombin or
TRAP on isoproterenol-induced cAMP accumulation. RAMEC
were preincubated for 10 min with either 0.05 or 0.5 Urml
 .  .hirudin HIR . Thereafter, 0.025 Urml thrombin THR or 2.5
mM TRAP were added, followed by 1 mM isoproterenol. The
experiment was terminated 5 min after addition of isoproterenol.
Results are expressed as percent of agonist-stimulated cAMP
 .levels depicted at column C and represent the mean"S.E.M. of
triplicate determinations from one representative experiment out
).of two that gave similar results. Asterisk denotes values
 .significantly P -0.02 lower than in column C.
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Fig. 4. Effect of PTX on the inhibitory action of thrombin on
 .agonist-induced cAMP accumulation in RAMEC. a Following
 .preincubation for 4 h with PTX 0.1–500 ngrml , the cells were
stimulated for 5 min with 1 mM isoproterenol, in the absence
 .  .squares and presence circles of 0.1 Urml thrombin. Results
are expressed as pmolrmg protein and represent the mean"
S.E.M. of triplicate determinations from one representative exper-
 .iment out of three that gave similar results. b–d Following
 .preincubation for 4 h with 100 ngrml PTX P , the cells were
 .stimulated for 5 min with 1 mM isoproterenol b , 1 mM IBMX
 .  .c , 100 mM forskolin, or d , in the presence and absence of 0.1
 .Urml thrombin T . Results are expressed as percent of agonist-
 .induced cAMP levels in each case column C , and represent the
mean"S.E.M. of 3 experiments each done in triplicate wells.
).  .Asterisk denotes values significantly P -0.01 lower than
in column C.
18.4"1.5 ngrml protein in unstimulated and PTX-
.treated cells, ns3 or isoproterenol-stimulated cAMP
 .levels Fig. 4b . Similarly, PTX did not alter the
IBMX-stimulatory effect on cAMP levels, but it abol-
 .ished the inhibitory action of thrombin Fig. 4c .
These results suggest that thrombin is coupled to
adenylyl cyclase through a PTX-sensitive G -protein.i
In forskolin-stimulated cells, PTX 100 ngrml for
.4 h , not only did not abrogate the inhibitory effect of
thrombin on cAMP accumulation, but it had a signifi-
cant inhibitory effect of its own, similar to the effect
 .of thrombin Fig. 4d . In the presence of PTX, throm-
bin was unable to significantly reduce cAMP levels
 .Fig. 4d . Similar results were obtained with higher
 .concentrations of PTX up to 1 mgrml . Thus, the
presumed direct activation of adenylyl cyclase by
w xforskolin 34 may involve a PTX-sensitive step.
3.5. Protein kinase C acti˝ators and inhibitors
Previous experiments suggested a cross-talk be-
w xtween PKC and adenylyl cyclase activity 28 . The
ability of thrombin to activate PKC in several EC
w xtypes is well documented 6,10 and is also implied
 .from our results see below, Section 3.7 . To assess
the possible involvement of PKC in thrombin-in-
duced inhibition of agonist-stimulated cAMP accu-
mulation, we used the PKC inhibitors H7 and stau-
rosporine, at concentrations considered rather specific
for PKC inhibition H7, 10 mM; staurosporine, 100
. w xnM 38 . In 2 independent experiments, each con-
taining 3 wells for each condition tested, preincuba-
tion for 30 min with either inhibitor had no effect on
either basal, isoproterenol-, or forskolin-stimulated
cAMP levels, in the presence or in the absence of
 .a-thrombin data not shown . It should be noted that
both inihibitors were )90% effective in inhibiting
PKC activity, as determined by using a commercial,
non-radioactive PKC assay MESACUP from Medi-
Fig. 5. Effect of PMA on agonist-stimulated cAMP accumula-
 .tion. The cells were stimulated for 5 min with either a 1 mM
 .  .  .isoproterenol ISO , or b 100 mM forskolin FOR , in the
 .presence and absence of PMA 100 nM for 10 min , or thrombin
 .THR, 0.1 Urml for 5 min , or both. Results are expressed as
pmolrmg protein and represent the mean"S.E.M. of triplicate
determinations from one representative experiment out of three
).that gave similar results. Asterisk indicates values signifi-
 .cantly P -0.01 higher in the presence than in the absence of
PMA.
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.cal and Biological Laboratories, Watertown, MA
according to the manufacturers’ instruction data not
.shown . Thus, the involvement of PKC in thrombin-
induced reduction of cAMP levels in RAMEC. is
unlikely.
PKC activation with PMA 1 mM for 5 min or 100
.nM for 10 min did not affect basal cAMP levels
20"4.5 and 24.3"6.4 pmolrmg protein in un-
stimulated and PMA-treated cells, respectively, ns
.3 , but it significantly potentiated isoproterenol-
stimulated cAMP levels when applied concomitantly
 .with the agonist Fig. 5a . By contrast, forskolin-in-
duced cAM2P production was unaffected by PMA
 .Fig. 5b . Interestingly, PMA partially reversed the
inhibitory effect of thrombin on cAMP levels induced
by either of the above agonists. For example, in the
case of isoproterenol-induced cAMP accumulation,
the inhibitory effect of thrombin was 93"5.6% in
the absence of PMA, but only 64.6"5% in its
 .presence ns3, and P-0.05, in both cases . In the
case of forskolin-induced cAMP accumulation, the
PMA-induced partial reversal of thrombin’s effect on
forskoln-induced cAMP is apparent from the data
shown in Fig. 5b. Collectively, our results with PMA
and PKC inhibitors suggest that, while thrombin-
activated PKC does not affect cAMP homeostasis,
PMA-activated PKC affects both the isoproterenol-
stimulated cAMP elevation and the thrombin-induced
inhibition of this elevation. This apparent dichotomy
may reflect differences in the nature of PKC activa-
tion by PMA and physiological agonists such as
w xthrombin 39 .
3.6. Intracellular Ca2q chelation
The regulation of adenylyl cyclase activity by
2q w xintracellular Ca has been well documented 17 . To
investigate the possibility that thrombin-induced Ca2q
elevation may be involved in the inhibitory effect of
this agonist on cAMP accumulation, we used the
cell-permeant Ca2q chelator BAPTA-AM. Incubation
of RAMEC with 25 mM BAPTA-AM for 60 min did
not affect basal cAMP levels 19.2"5 and 16.4"4
pmolrmg protein in unstimulated and BAPTA-AM-
.treated cells, respectively, ns3 , but it potently
reduced isoproterenol-stimulated cAMP levels both
 .in the absence and presence of a-thrombin Fig. 6a .
The inhibitory effect of thrombin, however, was not
Fig. 6. Effect of BAPTA-AM on agonist-stimulated cAMP accu-
 .mulation. The cells were stimulated for 5 min with either a 1
 .  .  .mM isoproterenol ISO , or b 100 mM forskolin FOR , in the
 .presence and absence of BAPTA-AM 25 mM for 60 min or
 .thrombin THR, 0.1 Urml for 5 min or both. Results are
expressed as pmolrmg protein and represent the mean"S.E.M.
of triplicate determinations from one representative experiment
out of three that gave similar results.
2q affected by intracellular Ca chelation 75.9"3.6
and 73.5"5% inhibition in the absence and presence
.of BAPTA-AM, respectively, ns3 . Similar results
were obtained in forskolin-stimulated cells, although
the inhibitory effect of BAPTA-AM was much more
 .potent in this case Fig. 6b . These results suggest
that, while intracellular Ca2q homeostasis is pivotal
for the generation of cAMP by extracellular stimuli,
thrombin-induced elevation of intracellular Ca2q is
inconsequential for the inhibitory effect of this pro-
tease on agonist-stimulated cAMP accumulation.
3.7. Thrombin stimulation of intracellular Ca2q
Several studies have shown that thrombin activates
phospholipase C and evokes subsequent Ca2q release
from intracellular stores in various types of EC re-
w x.viewed in 10 . However, no such studies have been
reported in RAMEC. We found that monolayers of
RAMEC, cultured under identical conditions as in the
cAMP measurement studies, responded to thrombin
 .0.1–1 Urml with a fast, transient increase in intra-
cellular Ca2q levels which peaked 15–30 s after
addition of the agonist and returned to almost basal
 .levels within 5 min data not shown . The nature of
the thrombin response is characteristic for inositol
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trisphosphate-induced Ca2q release from intracellular
stores. This result confirms that thrombin activates
the phospholipase C cascade also in RAMEC.
4. Discussion
The major finding of this study is that thrombin
inhibits cAMP accumulation in cultured microvascu-
 .lar EC. This action of thrombin i requires the
proteolytic cleavage and activation of the thrombin
 .receptor, and ii is sensitive to the bacterial toxin
PTX. Together, these findings suggest that the throm-
bin receptor in this cell type is negatively coupled to
adenylyl cyclase through a PTX-sensitive G -protein.i
To the best of our knowledge, our study is the first to
demonstrate inhibitory coupling of adenylyl cyclase
to the thrombin receptor in endothelial cells. Previous
studies found either no effect or increased cAMP
w xlevels in response to thrombin 3,24–27 . The reasons
for the differences between our findings and the
previous studies may reside in the types of EC used.
Most of the above studies were done in HUVEC or
other large vessel EC, while we used cells of mi-
crovascular origin. Our preliminary studies with di-
verse EC types confirm the previously reported stim-
ulatory effect of thrombin on adenylyl cyclase activ-
ity in HUVEC, but also suggest that the effect of
thrombin on intracellular cAMP levels in different
EC types can be inhibitory, stimulatory, or none,
depending on the tissue and species origin of the cells
Manolopoulos, V.G. and Lelkes, P.I., manuscript in
.preparation . This EC type-specific action of throm-
bin on intracellular cAMP homeostasis further ex-
tends our previous findings on the heterogeneity of
the adenylyl cyclase signaling system in various types
w xof EC 35 .
In an earlier study in fibroblasts, Magnaldo et al.
w x21 found a biphasic effect of thrombin on stimu-
lated adenylyl cyclase consisting of a PTX-sensitive
inhibitory effect at concentrations up to 0.1 nM
 .roughly equivalent to 0.01 Urml , followed by a
PKC-mediated potentiating effect at higher concen-
 .trations 0.1–10 nM . A similar mechanism may
account for the partial reduction of the inhibitory
effect that we found with higher thrombin concentra-
 .tions 0.25–1 Urml when forskolin or IBMX were
used to activate adenylyl cyclase Fig. 1 and data not
.shown . It should be noted, however, that no such
reversal was seen in the case of isoproterenol-
activated adenylyl cyclase even at a thrombin dose 1
.Urml equal to the highest dose used in the above
 .mentioned study data not shown .
The inhibitory effect of thrombin on adenylyl cy-
w xclase fulfilled several established criteria 9 required
for ascribing a cellular action of thrombin to prote-
olytic activation of the G-protein-coupled thrombin
 .  .receptor Table 2, Fig. 3 : i TRAP, a synthetic
peptide resembling the exposed NH -terminus of the2
thrombin receptor mimicked the inhibitory action of
 .thrombin. ii Hirudin, an established thrombin in-
hibitor, abolished the inhibitory action of thrombin
 .but not that of TRAP. iii g-Thrombin, which lacks
the fibrinogen binding site of a-thrombin but retains
full proteolytic activity, was able to reproduce the
 .inhibitory action of thrombin. iv PPACK-a-throm-
bin and DIP-a-thrombin, two thrombin analogs lack-
ing proteolytic activity, did not affect agonist-stimu-
lated cAMP levels. Thus, these results leave little
doubt that the effect of thrombin on adenylyl cyclase
activity is mediated through proteolytic activation of
the thrombin receptor.
The efficacy of g-thrombin is somewhat surpris-
ing, as the current model of thrombin receptor activa-
tion predicts that the anion-binding site of a-throm-
 .bin which is absent in g-thrombin may be important
in positioning the protease on the thrombin receptor
for appropriate cleavage of the receptor amino-
w xterminus 9 . However, this has not been proven to be
critical in every case and there are examples in the
literature showing that g-thrombin has almost the
w xsame efficacy as a-thrombin 40–42 . Also, in an-
other study in RAMEC, we found that a- and g-
thrombins show similar efficacy in stimulating extra-
w xcellular matrix protein deposition 43 . Moreover, the
possibility has not been ruled out that thrombin may
proteolytically activate distinct receptors in different
speciesrcell types, each of them with different
thrombin binding requirements for full activation.
w xIn agreement with previous reports 9,37 , our
results that trypsin and plasmin also reduce agonist-
 .stimulated cAMP levels Table 2 suggest that prote-
olytic cleavage of the thrombin receptor after an
arginine residue by proteases other than thrombin
may be sufficient for its activation. However, the
extent of proteolysis of the known thrombin receptor
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by these proteases was not determined, and it is thus
possible that other protease-activated receptors may
be involved in the observed effects of trypsin and
plasmin. For example, a protease-activated receptor
 .PAR-2 distinct from the thrombin receptor was
recently cloned in the mouse and subsequently found
w xalso in human EC 44,45 . This receptor is sensitive
to trypsin but not to thrombin, thus it is unlikely that
the action of thrombin observed in our study is
mediated through PAR-2 activation. Nevertheless, the
possibility cannot be excluded that the inhibitory
effects of trypsin andror plasmin on adenylyl cyclase
may be mediated through proteolytic activation of
PAR-2 or other protease activated-receptors likely to
w xbe discovered in the future 46 .
Pertussis toxin ADP-ribosylates and thus inacti-
vates the alpha subunit of the inhibitory G proteinsi
w xcoupled to adenylyl cyclase 12,19 . The presence of
G proteins that are ADP-ribosylated by PTX hasi
w xbeen demonstrated in virtually all cell types 13,47 ,
wincluding several types of endothelial cells 25,27,
x41,48–50 . Thus, although no direct detection of
ADP-ribosylation substrates in response to PTX was
performed in this study, the ability of PTX to negate
the inhibitory effect of thrombin on cAMP accumula-
tion in RAMEC strongly suggests that a G proteini
directly couples the thrombin receptor to adenylyl
cyclase in this cell type. Such a coupling has been
previously reported in platelets, fibroblasts, and
w xmegakaryocytes, but not in EC 19–22 . Interestingly,
in intact platelets, PKC activation with phorbol ester
reversed G -dependent, hormone-sensitive inhibitioni
of adenylyl cyclase, without affecting the G -indepen-i
w xdent portion of the inhibition 51 . In our study, PMA
 .had a similar effect Fig. 5 , further supporting the
idea that the inhibitory effect of thrombin on adenylyl
cyclase activity in RAMEC is mediated by G .i
Forskolin-stimulated cAMP levels were inhibited
by PTX to a similar extent as by thrombin. This is a
surprising result, as PTX is expected to potentiate
 .through removal of the G inhibitory componenti
rather than inhibit agonist-induced cAMP accumula-
tion, and it suggests that the presumed direct activa-
tion of adenylyl cyclase by forskolin might also
comprise a PTX-sensitive G protein. One possiblei
explanation may be provided by a recent study which
showed that certain adenylyl cyclase isoforms have
independent sites for interaction with G site 1,sa
.  .stimulatory and G site 2, inhibitory , and that highia
concentrations of G can interact with site 1 andia
w xactivate the enzyme 15 . Forskolin may somehow
produce high levels of G which in turn may activateia
adenylyl cyclase. Further studies are needed to clarify
this point.
Cross-talk between signal transduction pathways
plays an important role in the ability of single cells to
integrate multiple signal inputs into a unitary cellular
response. Extensive interactions between the phos-
pholipase C and adenylyl cyclase pathways have
w xbeen reported in several cell types including EC 17 .
In line with these reports, our results with PMA and
 .BAPTA-AM Figs. 5 and 6 show that both facets of
the phospholipase C signaling, i.e. PKC activation
and elevation of intracellular Ca2q, effectively modu-
late agonist-stimulated adenylyl cyclase activity in
RAMEC. However, the lack of effect of PKC in-
hibitors and BAPTA-AM argue against a role of
phospholipase C signaling in mediating the inhibitory
action of thrombin on adenylyl cyclase in this cell
type.
Adenylyl cyclase is expressed in at least 8 distinct
w xisoforms with different tissue distributions 13,17 .
All isoforms are responsive to forskolin and G , butsa
they are differentially regulated by other components
of the cellular signaling machinery, such as PKC,
2q w xCa , G -proteins, and G -protein subunits 14–17 .ia bg
Some clues as to the identity of the isoforms involved
in the effects of isoproterenol and thrombin in
RAMEC emerge from our results. Firstly, the fact
that thrombin activation of a G protein almost com-i
pletely inhibits the isoproterenol stimulatory effect
 .suggests that the adenylyl cyclase isoform s acti-
vated by isoproterenol are the ones sensitive to G .ia
Thus, isoforms I and II can be excluded, as inhibition
of isoform I by G is largely absent when theia
G -stimulated activity is examined, while activationsa
of G results in activation rather than inhibition ofi
w xisoform II 14 . In any case, isoform I is an unlikely
candidate in EC, as its expression has been shown by
w xseveral studies to be limited to the brain 13,47 .
Further, we found that PMA has no significant effect
on basal or forskolin-induced cAMP, but it strongly
 .enhances isoproterenol-induced cAMP levels Fig. 6 .
Similar results were recently reported in HT4 neural
cells, which express only adenylyl cyclase isoforms I
w xand VI 16 .
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In a previous study, we characterized the expres-
sion profile of adenylyl cyclase isoforms in RAMEC:
isoforms III and VI are predominant, followed by
small amounts of isoform V and only trace amounts
w xof isoforms II and IV 30 . Based on these data, we
hypothesize that isoform VI — and perhaps also V
— may be the principal adenylyl cyclase isoforms
mediating the effects of isoproterenol and thrombin
on cAMP homeostasis in RAMEC. Additional sup-
port for this hypothesis is provided by Taussig et al.
w x15 who showed that G - and forskolin-activatedsa
isoforms V and VI are strongly inhibited by G .ia
However, it should be noted that in a cell containing
many of the known isoforms of adenylyl cyclase, all
of which are regulated in a highly complex manner, it
is unlikely that a single isoform is solely responsible
for the observed effects on cAMP levels. Studies with
isoform-specific neutralizing antibodies or antisense
oligonucleotides are needed to verify this notion.
Both thrombin and cAMP regulate several func-
tions in EC, and often they do so in an opposing
fashion. For example, in HUVEC, thrombin induces
tissue factor synthesis and cell surface expression,
effects that can be inhibited by elevation of cAMP
w x4 . In the same EC type, thrombin-stimulated platelet
activating factor production is inhibited by agents
w xthat increase cAMP 6 . Also, thrombin is a potent
stimulator of EC monolayer permeability, while ele-
vated cAMP not only reduces the permeability of
quiescent EC monolayers, but also abolishes the stim-
w xulatory action of thrombin 5,8 . Moreover, in a chick
chorioallantoic membrane angiogenesis model,
w xthrombin stimulates angiogenesis 52 , while cAMP-
w xelevating agents potently inhibit it 53 . We hypothe-
size that, through its ability to inhibit adenylyl cy-
clase, thrombin may provide an endogenous system
to antagonize excessive signal transduction by ago-
 .nists e.g. adrenaline that exert their physiological
actions through activation of the adenylyl cyclase
pathway. Such a control system may be of special
relevance in EC at the adrenal medulla, which repre-
sent the first cell layer in the vasculature to be
exposed to circulating catecholamines produced by
chromaffin cells.
In conclusion, we have shown that thrombin in-
hibits basal and agonist-stimulated cAMP accumula-
tion in RAMEC; this inhibitory action requires prote-
olytic activation of the thrombin receptor and is
sensitive to PTX. These findings suggest that the
thrombin receptor in this cell type is negatively cou-
pled to adenylyl cyclase through a G -protein.i
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